138 related articles for article (PubMed ID: 3291602)
21. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
22. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
23. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Middleman MN; Lush RM; Figg WD
Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
[TBL] [Abstract][Full Text] [Related]
24. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
25. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
26. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
27. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback.
Lund TD; Munson DJ; Haldy ME; Setchell KD; Lephart ED; Handa RJ
Biol Reprod; 2004 Apr; 70(4):1188-95. PubMed ID: 14681200
[TBL] [Abstract][Full Text] [Related]
28. Comparative effects and mechanisms of castration, estrogen anti-androgen, and anti-estrogen-induced regression of accessory sex organ epithelium and muscle.
Neubauer B; Blume C; Cricco R; Greiner J; Mawhinney M
Invest Urol; 1981 Jan; 18(4):229-34. PubMed ID: 7451082
[TBL] [Abstract][Full Text] [Related]
29. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
Waxman J
Am J Clin Oncol; 1988; 11 Suppl 1():S16-8. PubMed ID: 3133943
[TBL] [Abstract][Full Text] [Related]
30. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
[TBL] [Abstract][Full Text] [Related]
31. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia.
Oesterling JE
J Androl; 1991; 12(6):381-8. PubMed ID: 1722794
[TBL] [Abstract][Full Text] [Related]
32. Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat.
Lefebvre FA; Séguin C; Bélanger A; Caron S; Sairam MR; Raynaud JP; Labrie F
Prostate; 1982; 3(6):569-78. PubMed ID: 6296803
[TBL] [Abstract][Full Text] [Related]
33. Carcinoma of the prostate: general concepts.
Rioja LA; Sanz J
Semin Oncol; 1991 Oct; 18(5 Suppl 6):2-8. PubMed ID: 1948119
[TBL] [Abstract][Full Text] [Related]
34. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
Gaillard-Moguilewsky M
Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
[TBL] [Abstract][Full Text] [Related]
36. [Bromocriptine and prostatic carcinoma: testosterone metabolism in relation to tumor grading (author's transl)].
Jacobi GH; Kurth KH; Altwein JE
Urologe A; 1979 Mar; 18(2):91-8. PubMed ID: 433016
[TBL] [Abstract][Full Text] [Related]
37. [LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
Senn E; Müller J; Alioth H
Schweiz Rundsch Med Prax; 1985 Nov; 74(48):1340-4. PubMed ID: 3003863
[No Abstract] [Full Text] [Related]
38. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Faure N; Lemay A; Laroche B; Robert G; Plante R; Jean C; Thabet M; Roy R; Fazekas AT
Prostate; 1983; 4(6):601-24. PubMed ID: 6415632
[TBL] [Abstract][Full Text] [Related]
39. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
Geller J; Albert J; Vik A
Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues.
Sandow J; Stoeckemann K; Jerabek-Sandow G
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):925-31. PubMed ID: 2126737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
